Recent Updates
Recently added Catalysts
BIVI Negative Sentiment Score: 25/100

BioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 – BIVI

Key Takeaway: BioVie Inc. is facing a class action lawsuit initiated by The Gross Law Firm, with a lead plaintiff deadline set for March 19, 2024. The allegations include claims of inadequate oversight during a critical Phase 3 clinical trial, exacerbated by the COVID-19 pandemic. It is asserted that due to reliance on contract research organizations, the trial data may be unreliable, leading to significant patient exclusions. The lawsuit further contends that the company's public statements were misleading regarding its operational compliance and business practices.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allegations of significant oversight failures in clinical trials.
  • The impact of COVID-19 negatively affected trial oversight.
  • Unreliable data from the Phase 3 clinical trial due to lack of oversight.
  • Concerns regarding misleading statements about the company's operations and practices.

Full Press Release Details

NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of BioVie Inc.
Shareholders who purchased shares of BIVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: August 5, 2021 to November 29, 2023
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) BioVie was not conducting proper oversight of its Phase 3 clinical trial; (2) the COVID-19 pandemic significantly and negatively impacted the Company's ability to adequately conduct proper oversight of the Phase 3 clinical trial; (3) due to lack of proper oversight and reliance on contract research organizations, the data from defendants' Phase 3 clinical trial faced a greater risk of being unreliable and that the majority of patients would have to be excluded from the clinical trial; (4) as a result of the significant exclusions from the trial results, the Phase 3 clinical trial would fail to meet its primary endpoints; and (5) statements about BioVie's business, operations, prospects, and compliance with current good clinical practices were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: March 19, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/biovie-loss-submission-form/?id=67520&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIVI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 19, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What was the class period for BioVie Inc. shareholders?

The class period for BioVie Inc. shareholders is from August 5, 2021, to November 29, 2023.

What are the allegations against BioVie Inc.?

Allegations include improper oversight of a Phase 3 trial and misleading statements about operations.

Is there a deadline for shareholders to register?

Yes, the deadline for shareholders to register is March 19, 2024.

Do I need to be a lead plaintiff to recover losses?

No, you do not need to be appointed as a lead plaintiff to participate in recovery.

How can shareholders monitor their case status?

Registered shareholders will receive updates through a portfolio monitoring software.

Last updated: Feb 21, 2024